# Acute Ischemic Stroke Diagnosis Market

> Acute Ischemic Stroke Diagnosis Market Research Report By Diagnostic Method (CT Scan, MRI, Ultrasound, Angiography), By Device Type (Imaging Devices, Monitoring Devices, Tests and Assays), By End Users (Hospitals, Diagnostic Centers, Research Institutions), By Technology (Radiology, Neuroimaging, Biomarkers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 7.8%
- **2025:** USD 2.50 Billion
- **2035:** USD 5.27 Billion
- **Key Players:** Siemens Healthineers, GE HealthCare, Philips, Canon Medical Systems, Viz.ai, RapidAI, Aidoc, Brainomix

**Report ID:** MRFR/HC/40391-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** November 18, 2026

**URL:** https://www.marketresearchfuture.com/reports/acute-ischemic-stroke-diagnosis-market-42055

---

## Market Summary

## Acute Ischemic Stroke Diagnosis Market Summary

The acute ischemic stroke diagnosis market was valued at USD 2.50 billion in 2025 and is projected to reach USD 2.68 billion in 2026, climbing to USD 5.27 billion by 2035 at a CAGR of 7.8% over 2026–2035. Two clinical catalysts anchor this trajectory. The DAWN and DEFUSE 3 trials stretched the thrombectomy window to 24 hours for patients selected by advanced imaging [4][5], and the 2023 SELECT2 and ANGEL-ASPECT trials extended benefit to patients with large ischemic cores [6][7]. Each expansion turns imaging from a confirmatory step into the gatekeeper for treatment.

Hospitals are replacing sequential, radiologist-only reads of non-contrast CT with automated multimodal pipelines that combine CT angiography, perfusion maps and algorithmic alerts. In 2018 the U.S. Food and Drug Administration granted De Novo authorization to the first computer-aided triage software for large-vessel occlusion [8], and the Centers for Medicare & Medicaid Services later approved a new-technology add-on payment of up to USD 1,040 per case [9]. That pairing of regulatory clearance and payment converted AI from a pilot project into a budget line. Photon-counting CT, cloud-hosted perfusion analysis and portable low-field MRI now extend the same logic to smaller sites.

North America leads the acute ischemic stroke diagnosis market with a 41.8% share in 2025, supported by dense comprehensive stroke center networks and established reimbursement. Asia-Pacific is the fastest-growing region at a 10.4% CAGR as China and India build certified stroke centers at scale. Europe ranks second, driven by national stroke programs and public AI funding. Over the next decade, competitive advantage will shift from scanner resolution toward minutes saved between hospital arrival and reperfusion.

## Key Report Takeaways

### • By Diagnostic Technology

- Computed Tomography (NCCT, CTA, CTP) held a 45.6% share of the acute ischemic stroke diagnosis market in 2025, reflecting its role as the first-line hyperacute modality.
- AI-enabled Stroke Decision-Support Software is the fastest-expanding technology, advancing at a 15.3% CAGR through 2035.

### • By AI Software Function

- Large-Vessel-Occlusion Detection accounted for 43.2% of AI software revenue in 2025.
- Perfusion Mismatch Quantification is projected to grow at a 17.4% CAGR as late-window protocols spread.

### • By Care Setting

- Emergency Department In-hospital settings captured a 66.2% share in 2025.
- Mobile Stroke Unit deployments are forecast to expand at a 16.9% CAGR.

### • By End User

- Hospitals held a 70.1% share of end-user spending in 2025.
- [Diagnostic Imaging](https://www.marketresearchfuture.com/reports/diagnostic-imaging-market-6765) Centers are set to grow at a 13.1% CAGR as outpatient CT capacity rises.

### • By Region

- North America commanded a 41.8% share of the acute ischemic stroke diagnosis market in 2025.
- Asia-Pacific is the fastest-growing region at a 10.4% CAGR.
- Europe generated USD 0.69 billion in 2025.

## Market Size and Forecast (2021–2035)

Market Research Future sized the acute ischemic stroke diagnosis market bottom-up from installed CT, MRI, ultrasound and angiography bases at stroke-capable facilities, procedure volumes per facility, AI software subscription and per-study pricing, and blood-based biomarker test volumes. Results were validated top-down against vendor segment disclosures, national stroke registries and hospital capital budgets, then triangulated through more than 350 primary interviews with neuroradiologists, stroke neurologists, procurement leads and vendor executives. Historical values for 2021–2024 reflect recovery from pandemic-era declines in stroke presentations; 2025 is the base year.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Expanding thrombectomy eligibility | +1.6% | Global | Long term (≥4 yrs) | [4][5][6][7] |
| FDA-cleared AI triage and add-on payments | +1.4% | North America, Europe | Medium term (2–4 yrs) | [8][9] |
| Aging populations and rising stroke burden | +1.2% | Global, Asia-Pacific core | Long term (≥4 yrs) | [1][2][24] |
| Radiologist workforce shortfall | +0.9% | Europe, North America | Short term (≤2 yrs) | [22] |
| Mobile stroke units and telestroke networks | +0.8% | North America, Europe | Medium term (2–4 yrs) | [15][16][23] |
| Public funding for clinical AI | +0.7% | Europe | Short term (≤2 yrs) | [10] |
| Tenecteplase approval for acute ischemic stroke | +0.5% | North America | Short term (≤2 yrs) | [12] |

### Expanding Thrombectomy Eligibility

Who is eligible for clot retrieval has changed due to late-window evidence. At 90 days, 49% of imaging-selected patients treated with thrombectomy in DAWN achieved functional independence, compared to 13% with medical therapy alone [5]; DEFUSE 3 reported 45% versus 17% [4]. Then, in large-core strokes that were previously thought to be incurable, SELECT2 and ANGEL-ASPECT demonstrated benefit [6][7]. In comprehensive and thrombectomy-capable hospitals, every newly qualified patient must undergo CT angiography in addition to perfusion or diffusion MRI, increasing the imaging intensity per patient.

### FDA-Cleared AI Triage and Add-On Payments

When the FDA approved the first computer-aided triage device for suspected large-vessel occlusion in 2018, regulators established a clear path for stroke algorithms [8]. CMS then made the first payment for an AI triage solution, a new-technology add-on payment of up to USD 1,040 per Medicare case [9]. This precedent encouraged numerous follow-on clearances covering occlusion detection, perfusion analysis, and bleeding triage and provided hospital finance departments with a justification for reimbursement.

### Aging Populations and Rising Stroke Burden

More than 12.2 million new strokes occur each year worldwide, and over 7.6 million of them are ischemic [1]. Stroke remains among the leading global causes of death and disability-adjusted life years [2]. The population aged 65 and older is projected to more than double to roughly 1.6 billion by 2050 [24], and incidence rises steeply with age. Larger patient pools translate directly into higher scan volumes, especially in China, India and Southeast Asia.

### Radiologist Workforce Shortfall

Imaging demand is outpacing specialist supply. The Royal College of Radiologists reported a 30% shortfall of clinical radiologists in the UK in 2023, projected to reach 40% by 2028 [22]. Comparable pressure exists in U.S. community hospitals that lack overnight neuroradiology cover. Automated pre-reads that flag occlusions within minutes let a single remote specialist supervise several spoke hospitals, so workforce gaps act as a direct purchase trigger for AI decision-support subscriptions.

### Mobile Stroke Units and Telestroke Networks

Prehospital diagnosis is moving onto the road. The BEST-MSU trial found that mobile stroke unit care produced better 90-day disability outcomes than standard ambulance transport [15], and the Berlin B_PROUD study reported similar functional gains [16]. In the United States, the FAST Act provisions of the Bipartisan Budget Act of 2018 removed geographic restrictions on Medicare telestroke consultations from 2019 [23], widening the hub-and-spoke model that depends on shared CT and AI image routing.

### Public Funding for Clinical AI

Governments are underwriting adoption costs. In June 2023 the UK Department of Health and Social Care launched a GBP 21 million AI Diagnostic Fund and committed to extending AI stroke decision-support to all 107 stroke units in England [10]. National programs of this kind shorten procurement cycles from years to months, set reference pricing for software, and give vendors population-scale deployment data that strengthens later tenders in other European health systems.

### Tenecteplase Approval for Acute Ischemic Stroke

The FDA approved tenecteplase for acute ischemic stroke in March 2025 [12]. Single-bolus administration simplifies thrombolysis and shortens door-to-needle time, which compresses the window available for imaging decisions. Faster lytic workflows push emergency departments to run non-contrast CT and CT angiography back to back with automated reads, and they support drip-and-ship transfers that rely on shared images between spoke and hub hospitals.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of advanced imaging and mobile units | −0.9% | Emerging markets, rural regions | Long term (≥4 yrs) | [15][17] |
| Time-limited and uneven AI reimbursement | −0.7% | North America, Europe | Medium term (2–4 yrs) | [9] |
| Regulatory compliance burden for AI devices | −0.5% | Europe | Medium term (2–4 yrs) | [11] |
| Data privacy and integration complexity | −0.4% | Global | Short term (≤2 yrs) | [21] |
| Limited evidence beyond large-vessel occlusions | −0.3% | Global | Short term (≤2 yrs) | [13] |

### High Capital Cost of Advanced Imaging and Mobile Units

Market Research Future projects a seven-figure purchase cost per truck prior to staffing for a fully functional mobile stroke unit that includes a CT scanner, telemedicine connections, and a specialized crew. Additionally, photon-counting CT systems are more expensive than traditional multislice scanners [17]. The availability of modern procedures outside of urban areas is limited since smaller institutions and public systems in lower-income nations frequently postpone these purchases [15].

### Time-Limited and Uneven AI Reimbursement

By their very nature, new-technology add-on fees are transient, usually lasting two to three years before expenses become part of regular diagnosis-related group rates [9]. Hospitals must use operational finances to pay for AI subscriptions once that window closes. Adoption is dependent on central funds or demonstrated reductions in length of stay and post-discharge disability because the majority of European systems currently do not have specific tariffs for algorithmic image analysis.

### Regulatory Compliance Burden for AI Devices

The EU Artificial Intelligence Act entered into force in August 2024 and classifies AI embedded in regulated medical devices as high-risk, with obligations for such products applying from August 2027 [11]. Vendors must layer AI Act documentation, data governance and post-market monitoring on top of Medical Device Regulation conformity work. Smaller developers face higher fixed compliance costs per product, slowing European launches.

### Data Privacy and Integration Complexity

Stroke AI must pull images from PACS, push alerts to mobile devices and write results into electronic health records within minutes. Each link raises security obligations under the HIPAA Security Rule in the United States [21] and GDPR in Europe. Hospitals with legacy PACS or restricted cloud policies face lengthy IT reviews, and integration projects can add months to deployment timelines.

### Limited Evidence Beyond Large-Vessel Occlusions

Expansion into smaller occlusions hit a setback in 2025, when the ESCAPE-MeVO and DISTAL trials found no benefit from thrombectomy for medium or distal vessel occlusions [13]. That result weakens the clinical case for algorithms that flag those lesions. Alert fatigue from false positives also erodes clinician trust where sensitivity thresholds are set aggressively.

## Opportunities

## Acute Ischemic Stroke Diagnosis Market Opportunities

### Stroke Center Buildout in Emerging Economies

The World Stroke Organization–Lancet Neurology Commission projects annual stroke deaths rising to 9.7 million by 2050, with lower- and middle-income countries carrying the overwhelming majority of that burden [25]. China, India and Brazil are certifying new stroke-ready hospitals that need CT angiography, perfusion software and teleradiology links from day one. Vendors offering bundled scanner-plus-AI packages with local service networks can capture greenfield demand in the acute ischemic stroke diagnosis market.

### Subscription, Outcome-Linked and Data Business Models

Software vendors are shifting from perpetual licenses to per-study and enterprise subscriptions, and some now tie fees to door-to-groin time improvements. De-identified, consented imaging and outcome data collected across networks also have value for trial recruitment, device development and federated model training that keeps patient data on site. Providers that structure data partnerships within GDPR and HIPAA limits can open a recurring revenue stream.

### Prehospital Blood-Based Biomarker Testing

Blood-based biomarker tests remain small but could reshape triage. A point-of-care panel that rules out intracranial hemorrhage in the ambulance would let crews start treatment pathways before arrival and route suspected occlusions directly to thrombectomy-capable centers. Diagnostics companies that validate panels against CT reference standards and secure clearance first will set the pricing benchmark.

### Portable MRI and Robotic Transcranial Ultrasound

Low-field portable MRI received FDA clearance in 2020 and now delivers bedside diffusion imaging for patients too unstable for transport [18]. Robotic transcranial Doppler systems automate vessel monitoring in ambulances and intensive care units. These devices suit secondary hospitals and emerging markets that cannot justify a dedicated stroke MRI suite.

### Late-Window Perfusion Analytics in Telestroke Hubs

Large-core and late-window selection depends on reliable perfusion mismatch maps [6][7]. Hub hospitals that interpret images for dozens of spokes need cloud-based perfusion processing that standardizes results across scanner brands. Vendors offering scanner-agnostic perfusion analytics with automated quality control can win network-wide contracts rather than single-site deals.

## Future Outlook

## Acute Ischemic Stroke Diagnosis Market Future Outlook

### AI Orchestration of the Stroke Pathway

Stroke software is moving from single-finding detection to orchestration that reads the scan, pages the team, books the angiography suite and tracks timestamps. Every minute of untreated large-vessel stroke destroys an estimated 1.9 million neurons [20], so platforms that remove manual handoffs carry measurable clinical value. By 2035, Market Research Future expects the acute ischemic stroke diagnosis market to be shaped by such platforms, with most thrombectomy-capable centers running automated activation for suspected occlusions.

### Platform Economics Across Hardware and Software

Imaging manufacturers are bundling AI into scanner contracts, while independent software vendors sell scanner-agnostic platforms across entire networks. [Siemens Healthineers](https://www.siemens-healthineers.com/en-us/clinical-specialities/neurology/stroke-care), with fiscal 2024 revenue above EUR 22 billion [17], illustrates the scale advantage hardware incumbents bring to bundling. GE HealthCare's 2024 acquisition of MIM Software signals that OEMs will keep buying analytics capability rather than building it [14].

### Decentralized and Prehospital Diagnosis

Diagnosis will increasingly begin before hospital arrival. Mobile stroke units, portable MRI and future blood-based biomarker panels push triage into ambulances and community hospitals [15][18]. This shift redistributes revenue from large hospital imaging departments toward compact devices and cloud services, and it favors vendors whose software can process images from many device types.

### Evidence, Regulation and Value-Based Care

Global stroke costs are projected to reach USD 2.31 trillion by 2050 [25], keeping payers focused on outcomes. Regulators are tightening oversight of clinical AI, with the EU AI Act setting the template [11]. Vendors that publish prospective outcome data and maintain post-market performance monitoring will win procurement decisions as hospitals move from pilot purchases to multi-year contracts.

## Segment Insights

## Acute Ischemic Stroke Diagnosis Market Segmentation

### By Diagnostic Technology

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Computed Tomography (NCCT, CTA, CTP) | 45.6% share | First-line imaging for every suspected stroke |
| Magnetic Resonance Imaging (DWI, SWI, ASL) | USD 0.46 Billion | Posterior circulation and wake-up stroke assessment |
| Carotid & Trans-cranial Ultrasound | 8.9% share | Bedside vessel monitoring and secondary prevention |
| Cerebral Angiography (DSA) | 5.1% CAGR | Confirmation during thrombectomy |
| Blood-based Biomarker Tests | 13.2% CAGR | Prehospital hemorrhage exclusion research |
| AI-enabled Stroke Decision-Support Software | 15.3% CAGR | Workforce gaps and reimbursement precedents |

Within the acute ischemic stroke diagnosis market, Computed Tomography (NCCT, CTA, CTP) remains the workhorse because non-contrast CT excludes hemorrhage, CTA localizes occlusions and CTP quantifies salvageable tissue in a single visit. Magnetic Resonance Imaging (DWI, SWI, ASL) serves wake-up and posterior strokes. AI-enabled Stroke Decision-Support Software grows fastest as subscription pricing fits constrained budgets, while Blood-based Biomarker Tests remain a small, high-growth niche awaiting validated prehospital panels.

### By AI Software Function

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Early-Event Triage & Alerting | USD 0.08 Billion | Automated team activation |
| Large-Vessel-Occlusion Detection | 43.2% share | Thrombectomy routing |
| Perfusion Mismatch Quantification | 17.4% CAGR | Late-window and large-core selection |
| Hemorrhage Exclusion | 12.1% share | Thrombolysis eligibility screening |

AI software spending in the acute ischemic stroke diagnosis market concentrates on Large-Vessel-Occlusion Detection, since every stroke center prioritizes rapid identification of thrombectomy candidates. Perfusion Mismatch Quantification grows fastest because late-window and large-core protocols select patients by tissue viability rather than elapsed time [6][7]. Early-Event Triage & Alerting and Hemorrhage Exclusion are increasingly sold together in single dashboards, simplifying IT integration for buyers.

### By Care Setting

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Emergency Department In-hospital | 66.2% share | Primary entry point for stroke patients |
| Mobile Stroke Unit | 16.9% CAGR | Prehospital CT and earlier treatment |
| Telestroke Hub & Spoke | USD 0.73 Billion | Specialist coverage for rural hospitals |

Care-setting demand across the acute ischemic stroke diagnosis market still centers on the Emergency Department In-hospital segment, where scanners, stroke teams and treatment converge. Mobile Stroke Unit deployments expand fastest from a small base as trial evidence supports better outcomes from prehospital scanning [15][16]. Telestroke Hub & Spoke networks form a large middle tier, buying image-sharing and remote-reading software that lets one hub supervise many community emergency departments.

### By End User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 70.1% share | Emergency imaging and thrombectomy infrastructure |
| Diagnostic Imaging Centers | 13.1% CAGR | Outpatient CT capacity and value-based care |
| Ambulatory Surgery Centers / Others | USD 0.27 Billion | Screening and follow-up imaging |

Hospitals dominate end-user spending in the acute ischemic stroke diagnosis market because they control emergency imaging, angiography suites and stroke teams. Diagnostic Imaging Centers grow fastest as value-based care pushes follow-up and carotid imaging toward lower-cost outpatient settings, with some centers adding non-contrast CT for hemorrhage exclusion before transfer. Ambulatory Surgery Centers / Others contribute screening and secondary prevention volumes rather than hyperacute diagnosis.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.8% share | AI triage subscriptions, mobile stroke units, photon-counting CT |
| Europe | USD 0.69 Billion | National AI programs, telestroke networks, AI Act compliance |
| Asia-Pacific | 10.4% CAGR | Stroke center certification, CT installed-base growth |
| South America | 5.3% share | Public hospital modernization, teleradiology |
| Middle East and Africa | USD 0.12 Billion | GCC tertiary hospital investment, imaging access |
| Total | USD 2.50 Billion | — |

Regional demand in the acute ischemic stroke diagnosis market tracks the density of thrombectomy-capable centers, reimbursement for advanced imaging and the maturity of telestroke networks. North America remains the revenue anchor, while Asia-Pacific supplies the fastest incremental growth.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 86.4% share of region | Comprehensive stroke center certification and AI add-on payments |
| Canada | 8.6% CAGR | Provincial telestroke programs |
| Mexico | USD 0.05 Billion | Private hospital CT upgrades |

The United States dominates regional acute ischemic stroke diagnosis market spending because certification bodies require around-the-clock CT angiography access at thrombectomy-capable and comprehensive stroke centers, and stroke-related costs already exceed USD 56 billion a year [19]. Telestroke coverage under the FAST Act provisions sustains demand for shared imaging in rural hospitals [23]. Canada relies on provincial hub-and-spoke networks, while Mexico's growth centers on private hospital groups in major metropolitan areas adding CT perfusion capability.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.2% share of region | Certified stroke unit network and high CT density |
| United Kingdom | USD 0.13 Billion | National AI stroke rollout |
| France | 7.4% CAGR | Regional thrombectomy center expansion |
| Italy | 11.6% share of region | Hospital imaging renewal |
| Spain | 8.1% CAGR | Regional telestroke codes |
| Rest of Europe | USD 0.14 Billion | Nordic and Benelux AI adoption |

Germany leads European spending through its dense network of certified stroke units and high per-capita CT availability. The United Kingdom has the most centralized AI adoption after committing decision-support software to every stroke unit in England [10]. France and Spain are expanding regional thrombectomy coverage, and vendors across the region are preparing high-risk AI documentation ahead of the AI Act's 2027 deadline for device-embedded software [11].

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 36.5% share of region | National stroke center certification program |
| India | 13.6% CAGR | Rising incidence and private hospital expansion |
| Japan | USD 0.12 Billion | Aging population and high MRI density |
| Australia | 7.9% share of region | Mobile stroke units and telestroke |
| South Korea | 11.2% CAGR | Rapid AI software clearances |
| Rest of Asia-Pacific | USD 0.06 Billion | Southeast Asian tertiary hospital buildout |

China accounts for the largest share of regional spending as provincial hospitals pursue national stroke center certification that mandates rapid CT angiography. India posts the fastest country-level growth because private hospital chains are adding thrombectomy suites in tier-two cities. Japan's elderly population and high MRI availability sustain diffusion-based protocols, while South Korea's domestic AI developers are clearing products quickly and exporting them across the region [2].

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.4% share of region | Public stroke line-of-care program |
| Argentina | 8.3% CAGR | Private hospital imaging upgrades |
| Rest of South America | USD 0.03 Billion | Teleradiology in Chile, Colombia and Peru |

Brazil leads South American demand through stroke care lines in the public health system and a growing number of thrombectomy-capable private hospitals in São Paulo and Rio de Janeiro. Argentina's private sector drives CT and perfusion software upgrades. Elsewhere in the region, teleradiology connects provincial hospitals with neurologists in capital cities, creating demand for cloud-based image routing and automated reads.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 11.5% CAGR | Tertiary hospital investment and AI strategies |
| South Africa | 18.7% share of region | Private hospital stroke programs |
| Rest of Middle East and Africa | USD 0.05 Billion | Donor-funded imaging access |

GCC states are the growth engine of the region, as Saudi Arabia and the United Arab Emirates fund new tertiary hospitals equipped with stroke imaging and AI from launch. South Africa's private hospital groups run the most mature stroke programs on the continent. Across much of Africa, limited CT access remains the binding constraint, and the WSO–Lancet Neurology Commission identifies imaging availability as a priority gap [25].

## Competitive Benchmarking

## Competitive Benchmarking

The acute ischemic stroke diagnosis market is moderately concentrated. Market Research Future estimates the top five vendors hold roughly 45–52% of revenue, with an overall HHI of about 650–800, though concentration rises well above that level within AI software alone. Imaging manufacturers leverage installed scanner bases to bundle analytics, while pure-play software vendors compete on speed of alerts, clinical evidence and scanner-agnostic deployment.

| Company | Est. Revenue Share Range | Key Offerings for Acute Ischemic Stroke Diagnosis | Strategic Positioning |
| --- | --- | --- | --- |
| Siemens Healthineers | ~11–14% | Photon-counting and multislice CT, stroke post-processing, angiography systems | Hardware leader bundling AI with scanner contracts |
| GE HealthCare | ~10–13% | Revolution CT platforms, MRI, partner AI integrations, MIM Software | Platform integrator expanding analytics through acquisition |
| Philips | ~8–11% | CT, MRI, interventional suites, enterprise imaging informatics | Workflow and informatics focus across the care pathway |
| Canon Medical Systems | ~6–9% | Wide-coverage CT perfusion, angiography, deep-learning reconstruction | Strong in Japan and Asia-Pacific perfusion imaging |
| Viz.ai | ~5–8% | LVO detection, care coordination and team alerting | Pure-play leader in AI care coordination |
| RapidAI | ~4–7% | Perfusion, LVO and hemorrhage analysis suite | Established perfusion standard in late-window trials |
| Aidoc | ~3–5% | Hemorrhage and LVO triage within enterprise AI platform | Multi-condition radiology AI platform |
| Brainomix | ~2–4% | e-Stroke imaging decision support | Anchored in UK national rollout, expanding in Europe |
| Nicolab | ~1–2% | StrokeViewer cloud-based stroke analysis | European telestroke-focused specialist |
| Hyperfine | ~1–2% | Swoop portable low-field MRI | Point-of-care MRI for bedside imaging |
| NovaSignal | ~<1–2% | Robotic transcranial Doppler ultrasound | Prehospital and ICU vessel monitoring |

## Recent News & Developments

## Recent News & Developments

- NEJM / SELECT2 and ANGEL-ASPECT investigators (February 2023): Two randomized trials showed thrombectomy benefit for large-core strokes, widening the pool of patients who need advanced CT and perfusion imaging [6][7].
- UK Department of Health and Social Care (June 2023): Launched a GBP 21 million AI Diagnostic Fund and committed to AI stroke decision-support in all stroke units in England, setting a national procurement benchmark [10].
- GE HealthCare (January 2024): Announced the acquisition of MIM Software, adding imaging analytics capability that strengthens its software bundling strategy [14].
- European Union (August 2024): The Artificial Intelligence Act entered into force, classifying device-embedded clinical AI as high-risk and raising compliance requirements for stroke software [11].
- Siemens Healthineers (November 2024): Reported fiscal 2024 results showing continued growth in imaging, supporting investment in photon-counting CT capacity used in stroke protocols [17].
- ESCAPE-MeVO and DISTAL investigators (February 2025): Trials found no thrombectomy benefit for medium and distal vessel occlusions, tempering demand for algorithms targeting those lesions [13].
- U.S. FDA (March 2025): Approved tenecteplase for acute ischemic stroke, simplifying thrombolysis and accelerating imaging-led emergency workflows [12].

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Imaging hardware, blood-based biomarker tests and AI decision-support software used to diagnose acute ischemic stroke across emergency, prehospital, telestroke and outpatient settings |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 2.50 Billion |
| Market Size in 2035 | USD 5.27 Billion |
| CAGR (2026–2035) | 7.8% |
| Fastest Growing Segments | Perfusion Mismatch Quantification (17.4% CAGR); Mobile Stroke Unit (16.9% CAGR); AI-enabled Stroke Decision-Support Software (15.3% CAGR); Diagnostic Imaging Centers (13.1% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Siemens Healthineers, GE HealthCare, Philips, Canon Medical Systems, Viz.ai, RapidAI, Aidoc, Brainomix, Nicolab, Hyperfine, NovaSignal |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How should hospitals compare scanner-bundled AI with independent stroke software in the acute ischemic stroke diagnosis market?**
A: Bundled AI lowers integration effort for acute ischemic stroke diagnosis market buyers on a single scanner brand. Independent platforms suit networks running mixed CT fleets, since one interface standardizes alerts across sites [3].

**Q: Which procurement metric matters most when buying stroke AI?**
A: Validated time savings from scan completion to team notification matter most. Buyers should request site-level timestamp data rather than headline sensitivity figures.

**Q: What role does neurovascular imaging play in deciding between transfer and local treatment?**
A: CT angiography at a spoke hospital confirms or excludes an occlusion before transfer. That prevents unnecessary helicopter or ambulance transfers and protects hub capacity [23].

**Q: What integration hurdle most often delays acute ischemic stroke diagnosis market software deployments?**
A: Hospital cybersecurity reviews of cloud image routing cause the longest delays. Pre-approved security documentation and on-premises gateway options shorten approval times [21].

**Q: Are blood tests likely to replace CT in the acute ischemic stroke diagnosis market?**
A: No. Blood panels may help rule out hemorrhage before arrival, but CT remains necessary to locate occlusions and assess salvageable tissue [3].

**Q: Which emerging use case could open new revenue for acute ischemic stroke diagnosis market vendors?**
A: Post-thrombectomy follow-up imaging is a growing opportunity. Automated infarct volume measurement supports discharge planning and outcome reporting for quality registries.

**Q: How does the EU AI Act affect investment decisions?**
A: Investors favor vendors with mature quality systems, since high-risk obligations add documentation and monitoring costs. Companies already holding CE marking under MDR face a smaller compliance gap [11].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/acute-ischemic-stroke-diagnosis-market-42055*
